SEVERE ASTHMA: INNOVATION FACING A PERSISTENT THERAPEUTIC CHALLENGE
May 14, 2026
“Investors can hardly ignore this therapeutic area, which represents a $25 billion market.” — RAPHAEL WISNIEWSKI, Andera Partners.
The most common chronic disease in children, moderate to severe asthma remains imperfectly treated by current inhalation devices, leading to a high impact on school absenteeism and the quality of life of young patients. A population that has become a priority for Andera Partners' long-standing partner, Raphaël Wisniewski.
BiotechFinances : Why does asthma attract less interest from investors today, even though this disease affects 1 in 10 children in France?
Raphaël Wisniewski : Th...
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo.
Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit.
At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas molestias excepturi sint occaecati cupiditate non provident, similique sunt in culpa qui officia deserunt.
Nam libero tempore, cum soluta nobis est eligendi optio cumque nihil impedit quo minus id quod maxime placeat facere possimus, omnis voluptas assumenda est, omnis dolor repellendus. Temporibus autem quibusdam et aut officiis debitis aut rerum.
RELATED ARTICLES
KURMA CLOSES BIOFUND IV AT €215M
The healthcare venture firm closes its fourth biotech fund, up 35%, and confirms a still-minority strategy in Europe: combining company creation and e
NEWFUND LAUNCHES HEKA, THE FIRST EUROPEAN FUND FOCUSED ON BRAINTECH
Fueled by the rise of AI, BrainTech is asserting itself as one of the most promising segments of digital health. With a €60 million fund, Newfund inte
JEITO CAPITAL CROSSES THE BILLION MARK!
By closing its second fund, Jeito II, at more than one billion euros, Jeito Capital posts a record raise and brings its assets under management to €1.